Source: PR Newswire

Press Release: Morphotek : Morphotek And Rockefeller University Form A Sponsored Research Agreement To Study The Immunosuppressive Effects Of The Tumor Shed Antigen CA125 And Its Potential Impact In Future Patient Therapies

EXTON, Pa., Dec. 11, 2017 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a Sponsored Research Agreement (SRA) with The Rockefeller University to expand its research efforts around the mechanisms by which the CA125 tumor shed antigen...

Read full article »
Est. Annual Revenue
Est. Employees
CEO Avatar


Update CEO

CEO Approval Rating

- -/100

Read more